Skip to main content
SpringerLink
Log in

Molekulare Diagnostik der HPV-Infektion

Molecular diagnosis of HPV infections

  • Schwerpunkt
  • Published:
Der Pathologe Aims and scope Submit manuscript

Zusammenfassung

Karzinogene humane Papillomviren (HPV) sind die Auslöser des Zervixkarzinoms und anderer anogenitaler Karzinome. Große randomisierte Studien haben gezeigt, dass HPV-Tests effektiv im primären Screening eingesetzt werden können. Andere Anwendungen für den HPV-Nachweis sind die Abklärung unklarer Zytologiebefunde und die Nachsorge nach Behandlung von Krebsvorstufen. Zahlreiche Verfahren sind entwickelt worden um DNA, RNA oder Proteine von HPV nachzuweisen. Diese Testverfahren haben sehr unterschiedliche Einsatzgebiete. Eine ausführliche Validierung von neuen HPV-Tests ist notwendig, bevor sie klinisch eingesetzt werden.

Abstract

Carcinogenic human papillomaviruses (HPV) cause the majority of cervical cancers and other anogenital cancers. Large randomized trials have shown that HPV testing can be efficiently used for primary cervical cancer screening. Other applications include the triage of abnormal cytology results and the follow-up of women after treatment. Many assays have been developed to measure DNA, RNA and proteins of HPV and the various tests can have very different applications. It is important to rigorously validate HPV assays before they are implemented in screening or clinical care.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Brink AA, Snijders PJ, Meijer CJ (2007) HPV detection methods. Dis Markers 23:273–281

    PubMed  Google Scholar 

  2. Burger EA, Kornor H, Klemp M et al (2011) HPV mRNA tests for the detection of cervical inträpithelial neoplasia: a systematic review. Gynecol Oncol 120:430–438

    Article  PubMed  CAS  Google Scholar 

  3. Castle PE, Solomon D, Wheeler CM et al (2008) Human papillomavirus genotype specificity of hybrid capture 2. J Clin Microbiol 46:2595–2604

    Article  PubMed  Google Scholar 

  4. Cogliano V, Baan R, Straif K et al (2005) Carcinogenicity of human papillomaviruses. Lancet Oncol 6:204

    Article  PubMed  Google Scholar 

  5. Cuschieri K, Wentzensen N (2008) Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 17:2536–2545

    Article  PubMed  CAS  Google Scholar 

  6. Doorbar J (2007) Papillomavirus life cycle organization and biomarker selection. Dis Markers 23:297–313

    PubMed  CAS  Google Scholar 

  7. Dünsing S, Munger K (2002) The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability. Cancer Res 62:7075–7082

    Google Scholar 

  8. Galgano MT, Castle PE, Atkins KA et al (2010) Using biomarkers as objective standards in the diagnosis of cervical biopsies. Am J Surg Pathol 34:1077–1087

    Article  PubMed  Google Scholar 

  9. Gravitt PE, Kovacic MB, Herrero R et al (2007) High load for most high risk human papillomavirus genotypes is associated with prevalent cervical cancer precursors but only HPV16 load predicts the development of incident disease. Int J Cancer 121:2787–2793

    Article  PubMed  CAS  Google Scholar 

  10. Kinney W, Stoler MH, Castle PE (2011) Special commentary: patient safety and the next generation of HPV DNA tests. Am J Clin Pathol 134:193–199

    Article  Google Scholar 

  11. Li N, Franceschi S, Howell-Jones R et al (2011) Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer 128:927–935

    Article  PubMed  CAS  Google Scholar 

  12. McCredie MR, Sharples KJ, Paul C et al (2008) Natural history of cervical neoplasia and risk of invasive cancer in women with cervical inträpithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 9:425–434

    Article  PubMed  Google Scholar 

  13. Meijer CJ, Berkhof J, Castle PE et al (2009) Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 yrs and older. Int J Cancer 124:516–520

    Article  PubMed  CAS  Google Scholar 

  14. Molijn A, Kleter B, Quint W, Doorn LJ van (2005) Molecular diagnosis of human papillomavirus (HPV) infections. J Clin Virol 32(Suppl 1):S43–S51

    Article  PubMed  CAS  Google Scholar 

  15. Parkin DM, Bray F (2006) Chapter 2: The burden of HPV-related cancers. Vaccine 24(Suppl 3):S3/11– 25

    Article  PubMed  Google Scholar 

  16. Schiffman M, Castle PE, Jeronimo J et al (2007) Human papillomavirus and cervical cancer. Lancet 370:890–907

    Article  PubMed  CAS  Google Scholar 

  17. Schiffman M, Khan MJ, Solomon D et al (2005) A study of the impact of adding HPV types to cervical cancer screening and triage tests. J Natl Cancer Inst 97:147–150

    Article  PubMed  Google Scholar 

  18. Schiffman M, Rodriguez AC (2008) Heterogeneity in CIN3 diagnosis. Lancet Oncol 9:404–406

    Article  PubMed  Google Scholar 

  19. Schiffman M, Rodriguez AC, Chen Z et al (2010) A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia. Cancer Res 70:3159–3169

    Article  PubMed  CAS  Google Scholar 

  20. Schiffman M, Wentzensen N, Wacholder S et al (2011) Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst 103:368–383

    Article  PubMed  Google Scholar 

  21. Schopp B, Holz B, Zago M et al (2010) Evaluation of the performance of the novel PapilloCheck HPV genotyping test by comparison with two other genotyping systems and the HC2 test. J Med Virol 82:605–615

    Article  PubMed  Google Scholar 

  22. Stoler MH, Wright TC Jr, Sharma A et al (2011) High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol 135:468–475

    Article  PubMed  Google Scholar 

  23. Walboomers JM, Jacobs MV, Manos MM et al (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12–19

    Article  PubMed  CAS  Google Scholar 

  24. Wentzensen N, Gravitt PE, Solomon D et al (2009) A study of Amplicor human papillomavirus DNA detection in the atypical squamous cells of undetermined significance-low-grade squamous inträpithelial lesion triage study. Cancer Epidemiol Biomarkers Prev 18:1341–1349

    Article  PubMed  CAS  Google Scholar 

  25. Wentzensen N, Knebel DM von (2007) Biomarkers in cervical cancer screening. Dis Markers 23:315–330

    PubMed  CAS  Google Scholar 

  26. Wheeler CM, Hunt WC, Joste NE et al (2009) Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst 101:475–487

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Boulevard, Rockville, MD 20852-7234, Maryland, USA

    N. Wentzensen

Authors
  1. N. Wentzensen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N. Wentzensen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wentzensen, N. Molekulare Diagnostik der HPV-Infektion. Pathologe 32, 461–466 (2011). https://doi.org/10.1007/s00292-011-1475-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00292-011-1475-6

Schlüsselwörter

Keywords

Search

Navigation